{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:20:07Z","timestamp":1788369607344,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jdiacomp.2025.108998","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T17:03:25Z","timestamp":1741021405000},"page":"108998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of efficacy and safety of pioglitazone and SGLT2 inhibitors in treating Asian patients in MASLD associated with type 2 diabetes: A meta-analysis"],"prefix":"10.1016","volume":"39","author":[{"given":"Lingyan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaojiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.108998_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: state of art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0020","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: a multisystem disease","volume":"14","author":"Pipitone","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0025","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"NASH clinical research network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0030","doi-asserted-by":"crossref","first-page":"630","DOI":"10.4093\/dmj.2021.0130","article-title":"Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"46","author":"Seo","year":"2022","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0035","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"Epidemiol. Glob. Health"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/6638306","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes mellitus: a bidirectional relationship","volume":"2020","author":"Muzica","year":"2020","journal-title":"Canadian Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0050","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3333","article-title":"Non-alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance","volume":"36","author":"Fiorentino","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0060","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus \u2014 mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00877","article-title":"NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment","volume":"10","author":"Xia","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.635556","article-title":"Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a Meta-analysis of randomized controlled trials","volume":"12","author":"Wei","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eprac.2021.09.013","article-title":"Antidiabetic medications for type 2 diabetics with nonalcoholic fatty liver disease: evidence from a network Meta-analysis of randomized controlled trials","volume":"28","author":"Ng","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0080","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12916-023-03129-6","article-title":"Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials","volume":"21","author":"Deng","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0090","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/jdi.13237","article-title":"Effects of sodium\u2013glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"11","author":"Xing","year":"2020","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102111","article-title":"Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"47","author":"Hameed","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12876-023-02948-4","article-title":"Effect of Empagliflozin and pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial","volume":"23","author":"Attaran","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0105","first-page":"843","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Placebo-Controlled Clinical Trial Diabetes Therapy"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102279","article-title":"Comparison between the effect of Empagliflozin and pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"48","author":"Hooshmand Gharabagh","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0115","first-page":"1364","article-title":"Comparison of Ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label","volume":"40","author":"Ito","year":"2017","journal-title":"Active-Controlled Trial Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0120","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040356","article-title":"The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: a randomized controlled trial","volume":"103","author":"Khaliq","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0125","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0130","first-page":"675","article-title":"Comparative efficacy of daglitazine or pioglitazone combined with metform in patients with type 2 diabetes mellitus and non-alcoholic fatty liver","volume":"39","author":"Qi Qi","year":"2020","journal-title":"Chin J New Drugs Clin Rem"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0135","first-page":"86","article-title":"Comparison on effect of empagliflozin versus pioglitazone on type 2 diabetes mellitustype complicated by non-alcoholic fatty liver disease","volume":"49","author":"Feng-tian","year":"2022","journal-title":"Chinese Journal of Practical Medicine"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11175144","article-title":"Nonalcoholic fatty liver disease and its complex relation with type 2 diabetes mellitus\u2014from prevalence to diagnostic approach and treatment strategies","volume":"11","author":"Diaconu","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/biom12060824","article-title":"NAFLD: mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0155","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASLEASD-EASO clinical practice guidelines for the management of nonalcoholic fatty liver diseases","volume":"64","author":"European Association for the Study of the Liver (EASL)","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0160","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0165","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","article-title":"The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments","volume":"14","author":"Garcia-Ropero","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0170","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00392-023-02330-0","article-title":"Liver fibrosis and outcomes of atrial fibrillation: the FIB-4 index","volume":"113","author":"Raposeiras-Roub\u00edn","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0175","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0180","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0185","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis[J]","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0190","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic Steatohepatitis","volume":"323","author":"Sheka","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0195","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of Weight Loss Interventions with Changes in biomarkers of nonalcoholic fatty liver disease","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0200","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0205","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1007\/s10620-022-07508-6","article-title":"MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups","volume":"67","author":"Kim","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0210","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4093\/dmj.2021.0095","article-title":"Sex differences of visceral fat area and visceral-to-subcutaneous fat ratio for the risk of incident type 2 diabetes mellitus","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0215","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3904\/kjim.2018.427","article-title":"Risk for metabolic syndrome in the population with visceral fat area measured by bioelectrical impedance analysis","volume":"36","author":"Jeon","year":"2021","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0220","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.atherosclerosis.2019.06.910","article-title":"Impact of abdominal fat distribution, visceral fat, and subcutaneous fat on coronary plaque scores assessed by 320-row computed tomography coronary angiography","volume":"287","author":"Tanaka","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0225","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/met.2020.0054","article-title":"Visceral adiposity index as a practical tool in patients with biopsy-proven nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"19","author":"Vural Keskinler","year":"2021","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0230","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.numecd.2020.09.031","article-title":"Increased visceral fat accumulation modifies the effect of insulin resistance on arterial stiffness and hypertension risk","volume":"31","author":"Antonio-Villa","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0235","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12929-017-0357-5","article-title":"Role of free fatty acids in endothelial dysfunction","volume":"24","author":"Ghosh","year":"2017","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0240","article-title":"The association of adiponectin and visceral fat with insulin resistance and \u03b2-cell dysfunction","volume":"34","author":"Uk","year":"2018","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0245","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/1751-2980.12980","article-title":"Liver and serum adiponectin levels in non-alcoholic fatty liver disease","volume":"22","author":"Mavilia","year":"2021","journal-title":"J Dig Dis"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0250","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.3748\/wjg.v20.i28.9330","article-title":"Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations","volume":"20","author":"Milic","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0255","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0265","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2147\/DMSO.S212715","article-title":"SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions","volume":"12","author":"Gharaibeh","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0270","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/molecules24183390","article-title":"Trilobatin, a novel SGLT1\/2 inhibitor, selectively induces the proliferation of human hepatoblastoma cells","volume":"24","author":"Wang","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.jdiacomp.2025.108998_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101620","article-title":"Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism","volume":"66","author":"Op den Kamp","year":"2022","journal-title":"Mol Metab"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725000510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725000510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T06:56:07Z","timestamp":1742972167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725000510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1056872725000510"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.108998","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of efficacy and safety of pioglitazone and SGLT2 inhibitors in treating Asian patients in MASLD associated with type 2 diabetes: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.108998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108998"}}